Correlation between muscle mass reduction and serum uric acid and urinary albumin in middle-aged and elderly type 2 diabetes men

This cross-sectional study correlated the muscle mass reduction with serum uric acid and urinary albumin in middle-aged and elderly men having type 2 diabetes. The study subjects were 288 middle-aged and elderly male patients with type 2 diabetes (T2DM) admitted to our hospital. They were divided into sarcopenia (n = 95) and non-sarcopenia (n = 193) groups based on whether diagnosed with sarcopenia or not. The relevant clinical information of patients was collected. Single factor analysis and multiple factor regression analysis were employed to explore the influencing factors of sarcopenia. A binary logistic regression analysis model was established for the sarcopenia probability in middle-aged and elderly men with T2DM. Hosmer and Lemeshow test evaluated the Goodness of fit of probability model. ROC (Receiver Operating Characteristic) curve was drawn by SPSS and the predictive value of prediction model was evaluated. The univariate analysis depicted that the patients in sarcopenia group compared to those in non-sarcopenia were older with lower BMI (Body Mass Index), lower UA (Uric Acid) and higher CRP (C-reactive Protein). The differences were statistically significant (p < 0.05). The binary logistic regression analysis exhibited that the age and UACR (Urine Albumin-to-Creatinine Ratio) were the risk factors, while BMI and UA were the protective factors for sarcopenia in middle-aged and elderly men with T2DM. For middle-aged and elderly male patients with T2DM, age and UACR were the risk factors, and BMI and UA were the protective factors for sarcopenia. The changes in above-stated indicators of patients with T2DM should be clinically monitored, and early and active intervention be given to high-risk groups for minimizing the sarcopenia occurrence.

Middle-aged and elderly people; Male; Type 2 diabetes; Reduced muscle mass; Blood uric acid; Urinary albumin; Inflammation

[1] Anagnostis P, Gkekas NK, Achilla C, Pananastasiou G, Taouxidou P, Mitsiou M, et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: a systematic review and meta-analysis. Calcified Tissue International. 2020; 107: 453–463.

[2] Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, et al. Prevalence and risk factors of sarcopenia in patients with diabetes: a meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2022; 107: 1470–1483.

[3] Aluganti Narasimhulu C, Singla DK. Amelioration of diabetes-induced inflammation mediated pyroptosis, sarcopenia, and adverse muscle remodelling by bone morphogenetic protein-7. Journal of Cachexia, Sarcopenia and Muscle. 2021; 12: 403–420.

[4] Ai Y, Xu R, Liu L. The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2021; 13: 93.

[5] Mu ZJ, Fu JL, Sun LN, Chan P, Xiu SL. Associations between homocysteine, inflammatory cytokines and sarcopenia in Chinese older adults with type 2 diabetes. BMC Geriatrics. 2021; 21: 692.

[6] Chai KC, Chen WM, Chen M, Shia BC, Wu SY. Association between preexisting sarcopenia and stroke in patients with type 2 diabetes mellitus. The Journal of Nutrition, Health & Aging. 2022; 26: 936–944.

[7] Lin TR, Huang XY, Hwu CM. Exercise experiences of older adults with diabetes and sarcopenia: a phenomenological study. Clinical Nursing Research. 2022; 31: 292–300.

[8] Chen LK. The vicious cycle in the development of diabetes mellitus and sarcopenia in older persons. Archives of Gerontology and Geriatrics. 2021; 95: 104437.

[9] Nakamura K, Yoshida D, Honda T, Hata J, Shibata M, Hirakawa Y, et al. Midlife and late-life diabetes and sarcopenia in a general older Japanese population: the Hisayama study. Journal of Diabetes Investigation. 2021; 12: 1899–1907.

[10] Remelli F, Maietti E, Abete P, Bellelli G, Bo M, Cherubini A, et al. Prevalence of obesity and diabetes in older people with sarcopenia defined according to EWGSOP2 and FNHI criteria. Aging Clinical and Experimental Research. 2022; 34: 113–120.

[11] Wen C, Lien AS, Jiang Y. Sarcopenia in elderly diabetes. Journal of Diabetes Investigation. 2022; 13: 944–946.

[12] Burgos R, García-Almeida JM, Matía-Martín P, Palma S, Sanz-Paris A, Zugasti A, et al. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and COVID-19 infection. Reviews in Endocrine and Metabolic Disorders. 2022; 23: 205–213.

[13] Formiga F, Moreno-González R, Corsonello A, Carlsson A, Ärnlöv J, Mattace-Raso F, et al. Diabetes, sarcopenia and chronic kidney disease; the screening for CKD among older people across Europe (SCOPE) study. BMC Geriatrics. 2022; 22: 254.

[14] Gao S, Yu L, Yi G, Li T, Chen Z, Ding J. Exercise intervention as a therapy in patients with diabetes mellitus and sarcopenia: a meta-analysis. Diabetes Therapy. 2022; 13: 1311–1325.

[15] Tanabe H, Hirai H, Saito H, Tanaka K, Masuzaki H, Kazama JJ, et al. Detecting sarcopenia risk by diabetes clustering: a Japanese prospective cohort study. The Journal of Clinical Endocrinology & Metabolism. 2022; 107: 2729–2736.

[16] Ma XY, Chen FQ. Effects of anti-diabetic drugs on sarcopenia: best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia. World Journal of Clinical Cases. 2021; 9: 10064–10074.

[17] Tamura Y, Shimoji K, Ishikawa J, Tachibana A, Kodera R, Oba K, et al. Associations between sarcopenia and white matter alterations in older adults with diabetes mellitus: a diffusion tensor imaging study. Journal of Diabetes Investigation. 2021; 12: 633–640.

[18] Che S, Meng M, Jiang Y, Ye X, Xie C. Perceptions of exercise and exercise instruction in patients with type 2 diabetes mellitus and sarcopenia: a qualitative study. BMC Geriatrics. 2022; 22: 892.